September 11th 2024
Richard Kim, MD, discusses the safety of NT-17 and next steps for its evaluation in pretreated microsatellite stable CRC and PDAC.
August 16th 2024
Richard Kim, MD, discusses the current treatment paradigm for patients with resectable CRC, as well as unmet needs in this population.
July 3rd 2024
Richard Kim, MD, on efficacy data for NT-I7 plus pembrolizumab in pretreated microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma.
April 11th 2024
The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.
April 4th 2024
Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.
Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.
March 28th 2024
Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.
Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.
March 21st 2024
Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.
Side effect profiles driven by fruquintinib use are discussed.
March 14th 2024
Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.
Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.
March 7th 2024
Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.
Medical experts provide key takeaways and impacts from the FRESCO-2 study.
February 29th 2024
Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.
Key safety considerations for the use of fruquintinib are explored.
February 22nd 2024
Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.
Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.
January 22nd 2024
Richard Kim, MD, discusses data from a real-world investigation of long-term responses with regorafenib in patients with metastatic colorectal cancer.